Investor Overview Press Releases November 5, 2026 Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update October 27, 2026 Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants October 27, 2026 Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma View all » Events Oct 27, 20268:00 AM EDT ATI-052 Phase 1b POC Results Update Sep 10, 20262:45 PM EDT 2026 Cantor Global Healthcare Conference Jun 4, 20262:00 PM EDT Jefferies Global Healthcare Conference View all » Feature Presentation August 2026 Corporate Presentation
November 5, 2026 Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
October 27, 2026 Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
October 27, 2026 Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
